Literature DB >> 83969

Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.

V Schirrmacher, K Bosslet, G Shantz, K Clauer, D Hübsch.   

Abstract

The syngeneic cytotoxic T-cell response against a metastasizing murine lymphoma variant was investigated and compared with the response against the non-metastasizing parental tumor line Eb. Anti-tumor cytotoxicity was not detectable in a 4-h 51Cr release assay in spleens taken directly from tumor-bearing animals (primary CMC). After restimulation in vitro (secondary CMC) however, high anti-tumor cytotoxic activity was detected. This activity was mediated by immune T lymphocytes as shown by its sensitivity to treatment with anti-Thy 1.2 serum and complement. Ten cells of the metastasizing tumor ESb, inoculated subcutaneously, were sufficient to raise a local tumor and metastases and to induce cytotoxic T memory cells in the spleens. In contrast, about 104 cells were required to raise a local tumor and to induce splenic cytotoxic T memory cells, when the parental tumor Eb was tested. The specificity studies of the anti-tumor cytotoxic activity demonstrated that cytotoxic T cells could distinguish unrelated, chemically induced syngeneic tumors and also recognize antigenic differences between the parental tumor Eb and its variant ESb. Eb and ESb tumor cells were recognized as carrying distinct antigens at the responder cell level, the stimulator cell level and the target cell level. The in vivo significance of these findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 83969     DOI: 10.1002/ijc.2910230216

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic.

Authors:  D S Hoon; I A Ramshaw
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  Differences in the metastatic potential of two sublines of tumor 3LL selected for resistance to natural NK-like effector cells.

Authors:  P Brodt; M Feldman; S Segal
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Logistics of tumor immunology.

Authors:  H Kirchner
Journal:  Klin Wochenschr       Date:  1982-01-04

5.  Syngeneic tumor cells can induce alloreactive T killer cells: a biological role for transplantation antigens.

Authors:  V Schirrmacher; D Hübsch; F Garrido
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

Review 6.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

7.  Selection and isolation of a new variant of DBA/2 mastocytoma P 815 X 2.

Authors:  G Bandlow; R Härtl
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

8.  Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages: in vitro analysis of tumor cell binding and cytostasis.

Authors:  V Schirrmacher; B Appelhans
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

9.  The selective nature of metastasis.

Authors:  J E Talmadge
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.

Authors:  V Schirrmacher; R Heicappell
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.